Form 4: Ptc Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Michael Schmertzler, a Director of Ptc Therapeutics, Inc., sold 2,500 shares of common stock on October 14, 2026.
Summary
- Open-market sale: disposed of 2,118 Common Stock at $59.52 ($126,063) on October 14, 2026; holds 1,291,976 after (Indirect).
- Open-market sale: disposed of 382 Common Stock at $60.14 ($22,973) on October 14, 2026; holds 1,291,594 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $149,037 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Michael Schmertzler — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Open-market sale | Common Stock | 2,118 | $60 | $126.1K | 1,291,976 |
| 2026-10-14 | Open-market sale | Common Stock | 382 | $60 | $23.0K | 1,291,594 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Open-market sale (2,118 shares) |
| 2026-10-14 | Open-market sale (382 shares) |
Keywords
insider transaction, Form 4, PTCT, PTC THERAPEUTICS, INC., bearish, Michael Schmertzler
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.